Xenon Pharmaceuticals Showcases XEN1101 Epilepsy Program at 35th International Epilepsy Congress
Retrieved on:
Monday, September 4, 2023
VANCOUVER, British Columbia, Sept. 04, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced a summary of its oral and poster presentations at the 35th International Epilepsy Congress (IEC) taking place in Dublin, Ireland from September 2-6, 2023.
Key Points:
- Clinically important improvements seen for all patients across important subscales of Seizure Worry, Social Functioning and Medication Effects and for seizure free patients across all QoL subscales
VANCOUVER, British Columbia, Sept. 04, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced a summary of its oral and poster presentations at the 35th International Epilepsy Congress (IEC) taking place in Dublin, Ireland from September 2-6, 2023. - Mr. Ian Mortimer, Xenon’s President and Chief Executive Officer, stated, “The IEC meeting in Dublin provides us with another key opportunity to connect with leading epileptologists and showcase our XEN1101 Phase 3 epilepsy program, which includes our ongoing X-TOLE2, X-TOLE3, and X-ACKT clinical trials in focal onset seizures and primary generalized tonic-clonic seizures, respectively.
- The SFG consisted of 29 patients (approximately 10.5% of those enrolled in the OLE).
- As a clinician, it is encouraging to see these QoL data, such as the improvements seen across all patients in Medication Effects, as this suggests that patients may benefit from XEN1101, perceiving it to be efficacious and generally well tolerated.